Appendix 4D and Interim Financial Report
Filed with ASX · · 25 pages · English
During the reporting period, significant advances were made in support of the development of the Company’s anti-infective portfolio. Highlights for the half year to 31 December 2025 included: • Research Abstract and Poster presentation at the 2025 Military Health System Research Symposium (MHSRS). The abstract presents expanded data of RECCE® 327 demonstrating activity against multiple high-priori
Recce Pharmaceuticals Ltd. on 6ix
Earlier from Recce Pharmaceuticals
- Recce Enters Second U.S. Department of Defense R&D Agreement
- Quarterly Activities/Appendix 4C Cash Flow Report
- AUD $5.3m R&D Rebate Received
- RCE Awarded Advanced Overseas Finding up to A$85m
- Hong Kong Patent Granted for RECCE Anti-Infectives
Later from Recce Pharmaceuticals
- RCE Investor Webinar Presentation Deck
- Brazil Patent Granted for RECCE Anti-Infectives
- Recce Signs Middle East Licensing Term Sheet
- Addendum to Recce Signs Middle East Licensing Term Sheet
- HREC Approval Accelerates Global Phase 3 DFI Strategy
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals